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The vascular endothelium plays a crucial role in the
regulation of vascular homeostasis and in preventing the
initiation and progress of cardiovascular disease by
controlling mechanical functions of the underlying vascular
smooth muscle. Three vasodilators: nitric oxide (NO),
prostacyclin, and endothelium-derived hyperpolarizing
factor, produced by the endothelium, underlie this activity.
These substances act in a co-ordinated interactive manner to
maintain normal endothelial function and operate as support
mechanisms when one pathway malfunctions. In this review,
we discuss recent advances in our understanding of how
gender influences the interaction of these factors resulting in
the vascular protective effects seen in pre-menopausal
women. We also discuss how endothelial NO synthase (NOS)
can act in both a pro- and anti-inflammatory action and
therefore is likely to be pivotal in the initiation and time
course of an inflammatory response, particularly with
respect to inflammatory cardiovascular disorders. Finally, we
review recent evidence demonstrating that it is not solely
NOS-derived NO that mediates many of the beneficial effects
of the endothelium, in particular, nitrite acts as a store of
NO released during pathological episodes associated with
NOS inactivity (ischemia/hypoxia). Each of these more
recent findings has emphasized new pathways involved in
endothelial biology, and following further research and
understanding of the significance and mechanisms of these
systems, it is likely that new and improved treatments for
cardiovascular disease will result.
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The endothelium is as a highly specialized, metabolically
active organ lining the luminal side of all blood vessels that
plays an integral role in the maintenance of vascular
homeostasis, mediated by a number of endothelium-derived
factors. The endothelium releases an array of vasoactive
mediators that not only alter the tone and growth of the
underlying smooth muscle but also regulate the reactivity of
circulating white cells, erythrocytes, and platelets, and govern
vascular permeability. Moreover, it appears that alterations in
the capacity of the endothelium to release these mediators
may be a major precipitating factor in many cardiovascular
disease states.
ENDOTHELIUM-DERIVED VASODILATORS
Of the vasodilator factors that the endothelium can release,
prostacyclin (PGI2),
1 nitric oxide (NO),2–4 and endothelium-
derived hyperpolarizing factor (EDHF)5–7 are the most
significant.
PGI2 is synthesized by cyclooxygenase (COX) isozymes, of
which, essentially, two have been identified. COX-1 is a
constitutive enzyme expressed in the vascular endothelium
and thought to contribute to the maintenance of vascular
homeostasis (a splice variant of COX-1, sometimes referred
to as COX-3, has also been reported8). COX-2 is an inducible
isozyme that is thought to be expressed in the cardiovascular
system (and immune cells) only during pathogenic episodes,
although there is some evidence to suggest that this isoform
is constitutively present in human endothelial cells.9 PGI2
elicits smooth muscle relaxation by activating specific cell-
surface receptors (IP) that are G-protein-coupled to adenylyl
cyclase and thereby elevate cyclic adenosine monphosphate
levels.10
NO is synthesized from L-arginine by NO synthases (NOS)
and causes vasodilatation via activation of soluble guanylyl
cyclase generating cyclic guanosine monophosphate.11 Under
physiological conditions, two ‘constitutive’ forms of NOS
play a role in NO production, predominantly endothelial
NOS (eNOS) and to a lesser extent neuronal NOS.12 A third
isoform, inducible NOS (iNOS), is expressed in a number
of inflammatory cell types and has an essential role in
vascular inflammation.13 The constitutive enzymes produce
low-level NO, important for maintaining vascular home-
ostasis, whereas iNOS activity results in ‘high-output’ NO
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production and this is thought to underlie its activity in
inflammation.
The identity of EDHF remains uncertain, although several
candidates have been proposed including Kþ ions, cyclic
adenosine monphosphate, cytochrome P450 2C products,
H2O2, spread of electrotonic current and, most recently,
C-type natriuretic peptide (CNP).7 However, it is universally
accepted that EDHF release/transmission from the endo-
thelial cell occurs following opening of endothelial SKCa and
IKCa.
14 Moreover, hyperpolarization of vascular smooth
muscle associated with EDHF activity, in the main, involves
activation of the Naþ /Kþ -ATPase and Kir.
There is considerable evidence to support the concept that
these substances not only act as vasodilators but they play a
multi-faceted role in vascular homeostasis, including inhibi-
tion of mitogenesis, platelet aggregation, and the extravasa-
tion of leukocytes.7,11,15–17
PHYSIOLOGICAL INTERACTION OF ENDOTHELIUM-DERIVED
MEDIATORS
In addition to their own distinct profile of activity, there is
clear evidence that these three endothelial mediators work
co-operatively in a complex but integrated manner to
maintain the health of the vasculature. Most notably, it
appears that each individual mediator possesses the capacity
to interact with components of the synthesis/activation
pathways for the other mediators and thereby manipulate
their activity. These relationships have been best character-
ized in terms of maintenance of vascular tone and occur at
two levels: first, in the physiological regulation of vessel
diameter, and second, as a compensatory mechanism
activated when the expression or activity of an alternate
mediator is deficient. For instance, endothelial regulation of
vascular tone is not uniformly consistent in terms of the
contribution of the three main vasodilators, NO, PGI2, and
EDHF. Although NO is the predominant endothelium-
derived vasodilator in conduit arteries, as one descends the
vascular tree the role of NO diminishes, whereas the
influence of EDHF increases.18 In this way, the absolute vaso-
dilator capacity of the arterial system is maintained. Studies
investigating the relationship between NO and EDHF have
indicated that basal NO tonically inhibits EDHF re-
sponses.19,20 Indeed, in many blood vessels EDHF responses
are only evident once NO production has been inhibited.19
The exact mechanisms involved in this interaction between
NO and EDHF remain unknown.
In a similar manner, the contribution of PGI2 (and other
COX products) to endothelium-dependent relaxation is often
evident only after inhibition of NOS,21 and accordingly, this
is thought to be owing to a tonic inhibitory effect of NO.
There is evidence to suggest that NO can both enhance and
inhibit COX activity and expression. These disparate effects
of NO are likely to reflect the specific nitrogen oxide species
involved and its concentration.22,23
There are several reports demonstrating upregulation of
PGI2 or EDHF in an environment where NO production has
been suppressed. For example, in gracilis muscle arterioles of
male eNOS knockout (KO) mice, endothelium-dependent
dilatation is maintained despite the absence of NO; this
compensation was shown to be PGI2-dependent as the
response was markedly attenuated by the COX inhibitor
indomethacin.24 Evidence supports the concept that this
provision of PGI2 originates from the upregulation of COX
enzyme expression or activity.25,26 However, evidence also
supports the thesis that EDHF is upregulated in eNOS KO
mice.27,28 Our own studies have demonstrated that, whilst
endothelial NO tonically antagonizes myogenic constriction
in resistance arteries of wild-type (WT) mice, in eNOS KO
animals rather than an exaggerated myogenic reactivity, these
responses remain normal as EDHF is upregulated to replace
the moderating influence of NO.27 This upregulation of
EDHF activity is thought to be linked to NO-mediated
inhibition of EDHF.19,20 Exactly how this is brought about is
uncertain, but studies using NO donors in rabbit carotid and
porcine coronary arteries demonstrate an NO-mediated
suppression of EDHF-mediated dilatation associated with
an interference with the synthesis and/or release of EDHF
rather than its mechanism of action.19,20 Indeed, patch-clamp
recordings in vascular smooth muscle cells revealed that NO
donors, which did not directly affect resting membrane
potential or EDHF-induced hyperpolarization, markedly
attenuated EDHF release from a donor segment.20 Similarly,
chronic inhibition of NO synthesis causes a change in the
factors mediating endothelium-dependent relaxation; several
studies have demonstrated a compensatory increase of PGI2
production and upregulation of COX expression.24,29,30 This
compensatory upregulation of PGI2 and/or EDHF following
suppression of NO production is also observed in models of
cardiovascular disease and in humans with cardiovascular
disease.21,26,29,31
There have been a number of excellent recent reviews
that have described in detail the roles of each of the
three vasodilators and their interactions,32–34 and the
impact of cardiovascular disease on their expression
and function,35,36 and therefore these areas will not be
dealt with in this review. Here, we focus on some areas
of endothelial biology that have come to the fore recently,
in particular, the impact of gender on endothelial
responses, the role of the endothelium in determining
inflammatory iNOS expression, and evidence demonstrat-
ing alternative endothelium-dependent sources of endo-
genous NO.
GENDER DIFFERENCES IN ENDOTHELIUM-DEPENDENT
RESPONSES
Several lines of evidence support the existence of gender
differences in endothelium-dependent vasodilator responses
in animals37–39 and humans.40,41 In sum, the data support the
concept that endothelium-dependent vasodilatation is en-
hanced in pre-menopausal females. Functionally, this differ-
ence in endothelial reactivity42,43 is thought to contribute to
the apparent protection of pre-menopausal women against
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cardiovascular disease.44 Many inflammatory cardiovascular
diseases are associated with a prevalence of ‘endothelial
dysfunction’, a phenomenon often attributed to the loss or
suppression of NO biological activity.35,45 Indeed, in many
cases, endothelial dysfunction precedes the onset of disease
and therefore this phenomenon may play an important role
in pathogenesis.46–48
ESTROGENS AND VASCULAR FUNCTION
The mechanisms involved in enhanced endothelial function
in females seem (intuitively) to be linked to female sex
hormones. For example, flow-mediated dilatation (FMD) of
the brachial artery is increased in females compared to males,
a difference temporally associated with the increase in serum
estradiol concentration that occurs during the menstrual
cycle. Indeed, the difference in FMD disappeared during the
M phase when serum levels of both estrogen and progester-
one were similar to those in male subjects.49 Similarly,
vasodilator responses to bradykinin are increased mid-cycle
in healthy women, when estrogen levels are at their highest.50
Further, young women with premature ovarian failure (or
premature menopause) have impaired endothelial function
that has been directly linked to sex steroid deficiency, as
treatment of these individuals for 6 months with estradiol
restored endothelial function.51 Ovariectomy also creates an
estrogen deficient state and in such patients endothelium-
dependent vasodilatation in the forearm is also attenuated.52
Together, these findings provide strong support for the thesis
that endogenous sex hormones, particularly estrogen, play an
important role in maintaining endothelial function in healthy
females.
There is an immense body of evidence demonstrating the
beneficial effects of estrogen on endothelial and vascular
function. Studies of post-menopausal women and ovariecto-
mized (OVX) animals52–58 have demonstrated that estrogen
administration improves endothelium-dependent vasodilata-
tion induced by vasodilators or flow.49–61 Similarly, the
endothelial dysfunction in women who suffer menopause in
the earlier stages of life, owing to surgical intervention, is
considerably improved following estrogen treatment;62 this
intimates that estrogen treatment in post-menopausal
women does not simply reverse age-related endothelial
dysfunction63 but rather that it reverses dysfunction owing
to a loss of female sex hormones. In the vasculature, estrogen
has been demonstrated to act in both a genomic and non-
genomic manner to influence endothelial function (for
review see 42,64,65). Relatively high micromolar concentra-
tions of estrogen (i.e., 100–1000 greater than physiological
levels) have direct acute vasodilator effects66 and this action
has been ascribed, in part, to endothelium-dependent
vascular relaxation.54,67 Alternatively, chronic exposure of
vascular cells and tissues to physiological concentrations of
estrogens alters the expression of a number of proteins
involved in the synthesis and activity of NO, PGI2, and
EDHF.65 Thus, the vasodilator effects of estrogens are
believed to play a major role in exerting a hypotensive and
anti-inflammatory phenotype in pre-menopausal women
that suppresses the development of atherosclerosis.
HORMONE REPLACEMENT THERAPY AND VASCULAR
FUNCTION
Despite the considerable body of evidence supporting a
cardioprotective role of estrogens, some studies have reported
that estrogen-induced improvement in FMD only occurs in
younger post-menopausal women68,69 and that estrogen
treatment does not augment endothelial function.70 As a
result, if and how any effect of estrogens on vascular
reactivity might translate to cardioprotection is a highly
controversial issue. This debate was fuelled by the failure of
hormone replacement therapy (HRT) in large-scale clinical
trials to confer protection from cardiovascular diseases in
post-menopausal women.71,72 It is thought that the dis-
appointing, and clearly unexpected, results of these trials may
have been owing to the timing of HRT administration with
respect to the onset of menopause;43 treatment should be
initiated at the start of menopause before the onset of
significant changes in cardiovascular function. This is an
issue that is being investigated by the recently set up Kronos
early estrogen prevention study.
Studies exploring the direct effects of HRT on the vascular
endothelium have also contributed to the controversy. Several
investigations show an improvement in endothelial function
in post-menopausal women on HRT.73–75 However, HRT is
commonly composed of both estrogens and progestins (the
latter to reduce risk of endometrial cancer induced by long-
term estrogen use76,77) and there is evidence that progestins
also alter endothelial function. For instance, progesterone
attenuates the favorable effects of estradiol on endothelium-
dependent dilatation in coronary arteries of OVX dogs78 and
in healthy post-menopausal women.79–81 In contrast, pro-
gesterone has also been shown to cause vasodilatation in
coronary and mesenteric resistance arteries.82–85
TESTOSTERONE AND VASCULAR FUNCTION
An alternative perspective to gender-dependent protection is
that an increase in male sex hormones, principally testoster-
one, is detrimental to vascular function. For example, young
women with polycystic ovary syndrome have associated high
levels of androgens and impaired brachial artery FMD
responses.86 In addition, hypogonadal men display exagger-
ated FMD responses that are reduced in matched controls
following treatment with testosterone.87 In contrast, femoral
arteries from male testicular feminized mice, which have
reduced levels of circulating testosterone, exhibited reduced
endothelial-dependent vasodilatation to acetylcholine
(ACh),88 and testosterone implant therapy improves, rather
than depresses, brachial artery FMD in post-menopausal
women using HRT.89 Moreover, trials of testosterone in heart
failure demonstrate an improvement of functional capacity
in men.90 The beneficial effects of testosterone in the latter
studies may in part be owing to local aromatization of
testosterone to estradiol within the vascular wall. This
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possibility is supported by the observation by Lew et al.91 that
suppression of endogenous estrogen production with an
aromatase inhibitor impairs FMD in young healthy men,
intimating that endogenous estrogens may play a direct
regulatory role in endothelial function in males. In an
analogous manner to estrogen and progesterone, testosterone
can induce vasodilatation through endothelium-dependent
mechanisms in arteries, including male and female canine
coronary conductance and resistance arteries,92 rat aorta, and
mesenteric arteries.93–95
GENDER-RELATED DIFFERENCES IN ENDOTHELIAL
MEDIATORS: NO
Hormonal modulation of endothelial and vascular function
may be via interaction with the NO pathway. Many studies
have shown that NO plays a major role in the beneficial effect
of sex hormones on endothelium-dependent vasodilatation
(for reviews see 65,66). Several animal studies have also
demonstrated clear increases in basal NO levels in the
presence of estrogens.39,96,97 Moreover, ovariectomy reduces
basal NO to levels equivalent in males,98–101 an effect that is
reversed by treatment of OVX animals with estradiol (for
review see 66). Additionally, 17-beta-estradiol (17b-estradiol)
enhances the sensitivity to endothelium-dependent vasodila-
tors in various blood vessels in both males and OVX females,
an effect that often is attributed to elevated endothelial NO
production.102,103 However, some studies report no change,
or even a decrease, in NO bioactivity following ovariectomy
and chronic treatment with 17b-estradiol.99,100,104–106 The
explanation for these conflicting results is difficult to pin-
point but may reflect heterogeneity with respect to the role of
endogenous NO in endothelium-dependent relaxation
throughout the vascular tree. Interestingly, perusal of the
literature demonstrates that basal NO production does
appear to be elevated in both conduit and resistance arteries
in response to estrogens; in general, however, instances in
which augmented NO-mediated responses are thought to
underlie enhanced endothelium-dependent dilatation occur
in larger conduit arteries,103,107–109 whereas in resistance
arteries, changes in NO bioactivity do not appear to play a
role in the altered vascular responsiveness.104,110,111
Clinical investigations are in agreement with the many
animal studies and demonstrate enhanced circulating levels
of NO in pre-menopausal females compared to males,112,113
and in post-menopausal women on estrogen replacement
therapy.114 Additionally, treatment of human endothelial cells
in culture with 17b-estradiol increases both basal and
stimulated NO release.115 Taken together these studies
suggest that estrogens elevate endothelial NO production
and that this may underlie the elevated levels of circulating
NO prevalent in females.
Both genomic and non-genomic mechanisms have been
proposed to account for estrogen-induced augmentation of
NO production. In terms of the genomic effects, activation of
specific estrogen receptors (membrane bound and/or cyto-
solic) causes nuclear translocation (of the hormone-receptor
complex) and activation of estrogen response elements in the
eNOS promoter, increasing enzyme expression and NO
synthesis. This phenomenon has been demonstrated in
cultured endothelial cells and arterial prepara-
tions.43,44,66,116,117 The effects of estrogen on the NO pathway
may also be related to its antioxidant effects.118,119 In human
umbilical vein endothelial cells, 17b-estradiol inhibits
nicotinamide adenine dinucleotide phosphate hydrogenase
oxidase expression and the generation of reactive oxygen
species and peroxynitrite.120 Furthermore, estrogen decreases
the generation of superoxide anions from cultured bovine
aortic endothelial cells and thereby enhance NO bioactiv-
ity.121
The non-genomic effects of estrogens are mediated via an
upregulation of eNOS activity rather than expression. In this
case, interaction of estrogen with estrogen receptors a and b
(both found in human endothelial cells; see for re-
view65,122,123), but primarily the former, results in ‘fast’
eNOS activation.124–127 This is thought to occur via several
pathways.128 The principal mechanism involves phosphor-
ylation of eNOS by protein kinase B/Akt, analogous to shear-
stress-induced increases in eNOS activity.129 However, there
is also evidence suggesting that alterations in the expression
of accessory proteins such as calmodulin, heat shock protein-
90, and caveolin-1 also mediate the estrogenic effects on
eNOS activity.71,103,130 However, this issue is controversial as
some studies report opposing effects of estrogens on
accessory protein expression directly contradicting the latter
hypothesis.131–134
The detrimental effect of progesterone on endothelium-
dependent relaxation appear to be related to decreased eNOS
levels, and increased consumption of NO by superoxide
anions.135 The endothelium-dependent effects of testosterone
are likely to be mediated at least, in part, through NO pro-
duction. Studies in rat aorta and mesenteric arterial bed and
coronary arteries from rabbit and dogs have demonstrated
that testosterone causes acute endothelium-dependent
vasorelaxation that is, in part, mediated by the activation
of eNOS.92,93,95,136 However, Li and Duckles137 showed that
an NOS inhibitor had no effects on vasorelaxation to
testosterone in rabbit coronary artery and aorta.
GENDER-RELATED DIFFERENCES IN ENDOTHELIAL
MEDIATORS: PGI2
The contribution of PGI2 to endothelium-dependent relaxa-
tion is also thought to be modulated by hormonal status. A
number of publications have documented enhanced PGI2
production following estrogen treatment of endothelial cells
and blood vessels of several species, including humans.138–140
Often this elevation in PGI2 is associated with an elevation in
COX expression,141,142 but more specifically it appears this
enhancement is the result of an upregulation of dilator
prostaglandins and downregulation of constrictor prosta-
glandins.139,143,144 For instance, estrogen treatment enhances
prostanoid-mediated vasodilatation in middle cerebral ar-
teries isolated from OVX female rats, whereas in the absence
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of estrogen arachidonic acid was actively converted to a
COX-1-dependent constrictor.139 In ovine arteries, it has
been suggested that this switch is related to an estrogen-
specific elevation of PGI2 synthase expression.
142 Estrogen
also suppresses production of a COX-sensitive vasoconstric-
tor143 and together these effects would shift the balance in
favor of vasodilator prostaglandin production. In contrast,
some studies show no role for COX and prostaglandins
on the estrogen-induced enhancement of endothelium-
dependent relaxation.145–147
Upregulation of prostaglandin synthesis in response to an
absence of NO bioactivity has been well-documented.27,30
This cross-talk between the NOS and COX pathways is also
thought to be modulated by estrogens. In mouse cerebral
arteries, from animals treated chronically with an NOS
inhibitor or with transgenic disruption of the eNOS gene,
estrogen treatment in vivo increases levels of vascular COX-1
expression and PGI2 production.
148 Moreover, in OVX
animals loss of estrogen is associated with a decrease in the
NO component of endothelium-dependent vasodilatation
and an upregulation of the COX component,148 whereas
estrogen treatment has been shown to produce an apparent
upregulation of the NO component of the endothelium-
dependent relaxation and a concomitant depression of the
COX-product component.149
The influence of other sex hormones on PGI2 bioactivity
remains unclear. For example, progesterone exerts a direct
relaxant effect on rat aorta that involves COX activation and
increased PGI2 production,
150 and both progesterone and
medroxyprogesterone acetate increase cultured human um-
bilical vein endothelial cell PGI2 production in a receptor-
dependent manner by enhancing COX-1 and COX-2
expression and activities.151 Yet, the concomitant adminis-
tration of progesterone with estrogen prevents the stimula-
tory effects of estrogen on PGI2 production in cultured
human umbilical vein endothelial cells.152 Akin to progester-
one, testosterone also causes acute vasorelaxation that is
dependent on endothelium-derived prostanoids.94 However,
testosterone treatment decreases PGI2 production in cultured
aortic vascular smooth muscle cells153 and in the aorta of
female rats.154
GENDER-RELATED DIFFERENCES IN ENDOTHELIAL
MEDIATORS: EDHF
A growing body of evidence supports the thesis that EDHF is
upregulated in females compared to males.155 However, as
the chemical identity of EDHF still remains elusive (see 7),
selective antagonists of EDHF are lacking and therefore the
true (patho)physiological role(s) of EDHF remains equivocal.
As a consequence, EDHF activity is regularly defined as the
response that persists in the presence of combined inhibition
of NO and PGI2 synthesis (i.e., by blocking NOS and COX,
respectively). This definition, however, has proved proble-
matic as inhibitors of NOS and COX are not isoform-
selective, do not result in complete inhibition, and often
have complicating inherent hemodynamic effects in vivo.
Moreover, NO and PGI2 can also elicit dilatation via
hyperpolarization of vascular smooth muscle resulting in
difficulties in delineating the actions of these endothelium-
derived vasodilators.156,157 To circumvent these difficulties,
we developed an eNOS/COX-1 double-knockout (dKO)
mouse or ‘EDHF mouse’.104 In these animals, we observed
that whilst males were markedly hypertensive, the female
animals were not. Indeed, this gender effect was duplicated in
mice deficient in either eNOS or COX-1, indicating that
irrespective of genotype females are protected against the
hypertensive consequences of deletion of these genes. More-
over, we reported that administration of bradykinin in female
dKOs caused potent dose-dependent depressor responses
whilst this endothelium-dependent vasodilator had no effect
in the male dKO animals (Figure 1). These findings provided
convincing evidence that the cardioprotective phenotype of
females (at least in terms of blood pressure) are mediated via
upregulation of EDHF rather than NO and/or PGI2
bioactivity, as has been proposed previously. Indeed,
examination of resistance arteries from these animals clearly
demonstrated that whilst NO and PGI2 are the predominant
endothelium-dependent vasodilators in isolated arteries from
males, in female blood vessels this response is due principally
to EDHF.104
Augmentation of the EDHF component of the dilator
response in females to endothelium-dependent stimuli,
including shear stress, ACh, and bradykinin, has also been
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Figure 1 | Bradykinin (BK) reduces blood pressure in female
but not male eNOS/COX-1 dKO mice in vivo. (a) Original trace
depicting typical responses to bolus injections of BK and sodium
nitroprusside (SNP) in (a) female and (b) male dKO mice. (c) Mean
dose-dependent decrease in blood pressure to BK in female (n¼ 4)
and male dKO mice (n¼ 3). Male significantly different (Po0.01) from
female (reproduced with permission by Scotland et al.104)
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demonstrated in a range of different arteries from various
species.40,104,158,159 This gender effect is thought to be owing
to the activity of estrogen. Indeed, EDHF responses are
reduced during diestrus, a period of comparatively low
estrogen levels,99 and elevated during pregnancy when
estrogen levels are very high.160 In addition, EDHF responses
evoked by ACh,71,99 shear stress,161 ADP,162 and Ca2þ
ionophore163 are all reduced by ovariectomy, an effect that
is reversed by treatment with 17b-estradiol.99,100,162,163 As
EDHF plays a greater role in endothelium-dependent
relaxation of resistance arteries than conduit arteries,19 our
findings in the dKO mice intimate that estrogen-induced
regulation of EDHF may be critical in determining peripheral
resistance in females and hence blood pressure.
Some studies have reported an inhibitory effect of
estrogen on EDHF, although this appears to occur mainly
within cerebral arteries. The EDHF response in isolated rat
middle cerebral arteries is reduced in female rats and
estrogen-treated OVX females as compared with male rats
and vehicle-treated OVX females.164 In vivo studies of pial
arterioles in female rats, OVX rats, and OVX rats with
oestrogen replacement came to the same conclusion that
estrogen downregulates EDHF.165
The mechanism underlying estrogen-mediated upregula-
tion of EDHF bioactivity merits further attention. Recent
findings suggest that treatment of OVX rats with 17b-
estradiol increases the expression of specific connexin
proteins (connexins 40 and 43) that constitute myo-
endothelial gap junctions71,163 and have been suggested to
play a key role in EDHF-mediated smooth muscle hyper-
polarization.166 In addition, estrogen enhances transcription
of CNP in mouse uterus167 and relaxations to CNP in female
porcine coronary artery are greater than in male arteries.168
As our work suggests that CNP acts as an EDHF in the
mesenteric and coronary circulation,169,170 it is possible that
increased CNP release/activity may account for enhanced
EDHF activity in females. Furthermore, EDHF responses are
associated with opening of KCa channels and treatment of
dogs with estrogen improves coronary vasodilatation
mediated by activation of such channels.171
INTERACTION BETWEEN ENDOTHELIAL AND INDUCIBLE NOS
IN THE REGULATION OF VASCULAR REACTIVITY
NO production from iNOS is the principal mediator of the
microbicidal and tumoricidal actions of macrophages.172 In
fact, iNOS is expressed by many cell types in response to
inflammatory cytokines (e.g., IL1-b, interleukin-2, interferon
gamma, and tumor necrosis factor-a) and bacterial metabo-
lites (e.g., lipopolysaccharide (LPS))173 and the NO produced
is cytotoxic and cytostatic to a number of pathogens and
tumor cells.174 However, inappropriate production of NO is
also thought to lead to host damage; for instance, ‘high-
output’ NO production from iNOS contributes to the
pathophysiological changes observed in sepsis.175 Thus, a
tight regulation of the expression and activity of iNOS is
vital. Recently, it has become apparent that eNOS-derived
NO plays a key role in the regulation of iNOS expression,
thereby conferring a novel, additional role for the endo-
thelium in an inflammatory response and extending our
understanding of the role of NO in particular.
FEEDBACK REGULATION OF NOS BY NO
Since the early 1990s it has been widely accepted that NO
exerts an autoregulatory feedback on its synthetic enzymes.
Both authentic NO and NO donors inhibit the activity of all
three NOS isozymes.176,177 Moreover, in endothelial cells,
prior exposure to supramaximal concentrations of NO
strongly suppressed NO biosynthesis in response to subse-
quent physiological stimuli.177 As a consequence of these
findings, it was hypothesized that high levels of NO,
produced endogenously by iNOS, would inhibit eNOS
activity. Such a mechanism might underlie the endothelial
dysfunction associated with inflammatory cardiovascular
disorders.
Experimentally, most of the evidence linking iNOS-
derived NO production with eNOS dysfunction has been
conducted using animal models of sepsis, induced primarily
by the administration of the gram-negative bacterial cell wall
component LPS or endotoxin.175 In several species exposed
to endotoxin, endothelial dysfunction occurs that is char-
acterized by loss of NO-dependent responses178,179. More-
over, this phenomenon is associated with vascular iNOS
expression.180,181 The link between iNOS-derived NO and
endothelial dysfunction was confirmed by studies in our
laboratory using iNOS KO animals.182 In WT animals, we
demonstrated that LPS caused vascular iNOS expression
associated with a 10-fold increase in circulating NO levels.
This was accompanied by reduced eNOS expression and
inhibition of endothelial function (demonstrated by suppres-
sion in the endothelium-dependent relaxation to ACh; see
Figure 2). These effects of LPS were absent in iNOS KO
animals proving unequivocally a role for iNOS in mediating
endotoxemia-induced endothelial dysfunction.183 In these
studies, we concluded that iNOS-derived NO inhibits eNOS
activity not only by biochemical means (e.g., negative
feedback regulation at the heme active site as described
above) but also genetic effects, as eNOS expression was
suppressed in WT, but not iNOS KO, animals exposed to
LPS. This work is supported by similar findings using iNOS
inhibitors where LPS-induced suppression of endothelial
responses evoked by eNOS activation is blocked.183–185
ENDOTHELIAL NOS-DERIVED NO AND REGULATION OF iNOS
In addition to the autoinhibitory actions of NO, recent
evidence suggests that NO plays a dual role in the regulation
of iNOS expression such that under certain conditions NO
can act in a proinflammatory manner. This biphasic effect of
NO has been shown to be mediated by changes in the
transcription factor nuclear factor-kappa B (NFkB).186
Inflammatory stimuli, including infectious organisms and
cytokines, result in an elevation of free cytoplasmic NF-kB,
which then translocates to the nucleus where it binds to the
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promoter regions of various inflammatory genes including
iNOS.187,188 We have shown that increasing concentrations of
exogenous NO exert differential effects on LPS-induced iNOS
expression in macrophages and that this is associated with
changes in NF-kB activity. More specifically, at low
concentrations of NO, NF-kB levels are raised and conversely,
and at high NO concentrations, NF-kB levels and DNA-
binding activity are suppressed.186,189 Subsequently, we have
demonstrated that the stimulatory effect of ‘low’ NO levels
on macrophage iNOS expression is not only brought about
by exogenously provided NO but also by endogenous eNOS-
derived NO in a cyclic guanosine monophosphate-dependent
process.190,191 For example, stimulation of macrophages
derived from the bone marrow of eNOS KO mice with LPS
produces a suppressed (B50%) and delayed iNOS expression
in comparison to cells from WT animals.190 Moreover, our
studies have shown that this effect of eNOS-derived NO to
promote iNOS expression also extends to the vasculature
in vitro and in vivo such that maximal expression and activity
of LPS-induced iNOS is dependent on eNOS-derived NO.
Consequently, we hypothesized that LPS causes an acute
increase in eNOS activity (via an effect on heat shock
protein-90 and protein kinase B/Akt) to generate levels of
NO commensurate with its augmentation of NF-kB activity
that then stimulates iNOS protein synthesis.192,193
Taken together, these data highlight a key, biphasic
regulatory role for NO that governs iNOS expression. In
the initial stages of an inflammatory response, eNOS-derived
NO augments NF-kB activity and facilitates iNOS expression
to expedite host defence. Following iNOS expression and
‘high-output’ NO production (e.g., to combat infection), the
elevated levels of NO exert a negative effect on NF-kB activity
and turn off subsequent iNOS transcription and inhibit
eNOS expression and activity. Thus, it appears that although
eNOS acts predominantly as an anti-inflammatory protein,
producing an array of effects including endothelium-
dependent vasodilatation, and inhibition of leukocyte and
platelet activation, under the appropriate circumstances it
fulfils an integral, proinflammatory role in facilitating iNOS
expression (and potentially other proinflammatory proteins
with NF-kB binding sites in their promoter region including
COX-2, interleukin-6).
ALTERNATE SOURCES OF ENDOGENOUS NO
In contrast to endothelium-derived NO, which has well-
established and important effects in the regulation of vascular
tone, its oxidative metabolite nitrite was until recently
considered to be physiologically inert. The only interest in
the physiological generation of nitrite was as a stable
metabolite and index of NO production (in combination
with nitrate). However, evidence is now emerging that nitrite
serves as a storage form of NO, which is released
preferentially under acidic and/or hypoxic conditions and
may thereby provide a vital reservoir of NO that supplements
NOS activity during pathological episodes.
It had previously been suggested that NO may be
transported in the blood in the form of a more stable
S-nitrosothiol, by interacting with free cysteine residues in,
for example, albumin194,195 or hemoglobin.196–200 Although
early studies, supporting this thesis, suggested high circulat-
ing levels (mM),194,201 subsequent reports have measured
considerably lower levels. Indeed, using an electron para-
magnetic resonance spectrometry assay for S-nitrosothiols
that we recently developed, we found that plasma
S-nitrosothiols were below the limit of detection of 25 nM in
9 of 12 healthy volunteers.202 Such low levels of S-nitrosothiols
question their potential physiological relevance.203–206 In
contrast, the levels of plasma nitrite we measured were much
higher B420 nM,202 in line with other studies that indicate a
range of 0.1–0.5 mM207–211 (the majority (460%) is carried by
erythrocytes; Dejam et al.212), although tissue concentrations
of nitrite are even greater than plasma, with levels in the rat
heart of 5–40 mM and aorta in the low mM range.213,214
The main source of nitrite has been considered to be from
the oxidation of NO derived from NOS, with one study
showing that 70% or more of plasma nitrite was derived from
eNOS.210 However, there is also a non-endothelium-depen-
dent source of nitrite derived from the diet, either directly
from dietary nitrite (used to preserve meat and protect
against botulism) or indirectly from the enterosalivary
circulation of dietary nitrate (principally from green leafy
vegetables). In the latter, up to 25% of ingested nitrate is
concentrated in the salivary glands, secreted in the saliva
and then reduced by bacterial nitrate reductases on the
surface of the tongue producing nitrite, which is then
swallowed.207,215–217
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Figure 2 | iNOS underlies sepsis-induced endothelial dysfunction.
Effect of LPS (12.5 mg/kg intravenously, 4 or 15 h pre-treatment) on
relaxation responses of mesenteric resistance arteries. Concentration
response curves to ACh in (a) WT and (b) iNOS KO (n¼ 5–14) and
SPER-NO in (c) WT and (d) KO (n¼ 7–11) mesenteric resistance
arteries. Values shown are mean7SEM. Statistical analysis using
two-way analysis of variance.
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Although high concentrations of nitrite have long been
known to cause vasodilatation, even until quite recently, it
was thought that nitrite at near-physiological concentrations
lacked vasodilatory activity.211 Evidence for a vasodilatory
action of nitrite per se dates back to 1953 when Furchgott
relaxed rabbit aortic strips with high concentrations of
acidified nitrite;218 however, the mechanism of dilatation was
unknown. More recently, Modin et al.,219 demonstrated that
physiological concentrations of nitrite relaxed rat aortic rings
at acidic pH 6.6, a pH reminiscent of ischemia, via the
generation of NO (through intermediates including nitrous
acid (HNO2)) and the consequent activation of soluble
guanylyl cyclase. However, other studies have demonstrated
vasodilatation under non-ischemic conditions, where acido-
sis is unlikely to account for NO production. For example,
the ingestion of large amounts of oral nitrite reduces blood
pressure in vivo in spontaneously hypertensive rats.220–222 The
mechanism likely to account for the majority of the
vasodilator effects of nitrite under normal physiological
conditions is via the reduction of nitrite to NO by deoxy-
hemoglobin. The oxidation of human deoxyhemoglobin by
nitrites producing methemoglobin and NO was first
described by Doyle et al.223 in 1981. However it was not
until 2003 that the physiological relevance was demonstrated
by Gladwins group who demonstrated vasodilator activity of
near-physiological concentrations of intra-arterial nitrite into
the human forearm224 associated with elevations of iron-
nitrosylated hemoglobin, the product of the reaction between
NO and deoxyhemoglobin. This study followed Gladwin’s
previous work demonstrating circulating arterial–venous
plasma nitrite gradients in the human forearm, which
increased during hand-grip exercise, suggesting that nitrite
was providing a source of NO.204 Tsuchiya et al.,225,226 sub-
sequently, showed that the ingestion of nitrite also produced
nitrosylhemoglobin, and moreover the co-administration
of nitrite with the NOS inhibitor, NG-nitro-L-arginine
methyl ester, over 3 weeks attenuated the development of
hypertension.
An additional ‘nitrite reductase’ that may contribute to
nitrite-induced vasodilatation is xanthine oxidoreductase
(XOR). In addition to the hypoxemia and increased
deoxyhemoglobin that develops during ischemia, the acidosis
that develops creates a reducing environment that may favor
the chemical reduction of nitrite to NO, as described above.
Indeed, this was demonstrated by Zweier et al.,214 in 1995 in
the isolated perfused Langendorff heart where NO is
produced from nitrite once the pH drops below 6.0 following
10 min global ischemia. Such a source of NO may be
particularly important, as the normal production of NO
from NOS and L-arginine is dependent on oxygen, which is
rapidly depleted in ischemia. At the time, Zweier considered
it likely that the degree of acidosis per se was sufficient to
account for the nitrite reduction, without the need for
enzymatic activity. We have more recently demonstrated that
this production of NO from nitrite is dependent on
endothelial XOR in both rat and human myocardium (and
this in the absence of any exogenously applied superoxide
dismutase).227 XOR, a complex molybdoflavoprotein, was a
likely candidate as it possesses structural similarity to
bacterial and plant nitrate/nitrite reductases and is an
endothelial enzyme that had previously been shown in its
isolated purified form to reduce nitrite to NO, a process that
is enhanced in acidic conditions and under low oxygen
tensions.228,229 Moreover, the activity of XOR is upregulated
in atherosclerosis (which predisposes to myocardial ischemia/
infarction): in patients with coronary artery disease, en-
dothelium-bound XOR activity was found to be increased by
4200%.230 We found that the application of both low and
high concentrations of nitrite (10 and 100 mM), far from being
inactive or damaging, had marked functional effects in the
Langendorff model of ischemia–reperfusion: nitrite was
highly protective in terms of improving the recovery of left
ventricular function, reducing coronary tone on reperfusion
and reducing infarct size.227 These effects were blocked by the
NO scavenger carboxy-PTIO, suggesting that the protective
effect of nitrite was through its conversion to NO. This
therefore suggests the involvement of XOR in a protective
process. XOR is usually associated with causing damage
through its production of oxygen-free radicals, including
superoxide anion.231 However, as our data suggest, if XOR is
presented with nitrite as an alternative substrate, the resultant
effects of its activity may be protective, via its production of
NO rather than damaging. Also nitrite will compete with
oxygen for electrons across XOR, which may inhibit the
reduction of oxygen to potentially damaging superoxide. The
cytoprotective effects of similar, and even lower, concentra-
tions of nitrite have subsequently been demonstrated in
ischemia–reperfusion experiments in the mouse heart and
liver in vivo.232 Nitrite reduction in these studies was
associated with the formation of iron-nitrosylated hemoglo-
bin, suggesting the same mechanism involving deoxyhemo-
globin previously demonstrated for vasodilatation. These
studies therefore support a role for nitrite as an important
store of protective NO during ischemia–reperfusion. The
cytoprotective effects of nitrite do not appear to be limited to
the heart and the liver: nebulized sodium nitrite was shown
by Hunter et al.,233 to produce a marked reduction in
hypoxia-induced pulmonary hypertension in newborn lambs
by causing a selective pulmonary vasodilatation. Also, the
intravenous infusion of sodium nitrite over 2 weeks caused
complete inhibition of cerebral vasospasm in a model of a
ruptured intracranial aneurysm in primates.234
Other enzymes besides XOR may act as nitrite reductases:
these include the mitochondrial enzymes cytochrome c
oxidase235 and the bc1 complex,
236 with the latter demon-
strating significant nitrite-reductase activity. Also, it would
follow that if deoxyhemoglobin has nitrite-reductase activity,
deoxymyoglobin might be expected to possess similar
activity, and indeed myoglobin has been shown to have
nitrite-reductase activity in its deoxy form.235,237
Although most of the evidence to date for the physio-
logical effects of nitrite appears to relate to it acting as a store
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of NO, there is very recent evidence that nitrite also has direct
effects. Bryan et al.213 found that nitrite increases cyclic
guanosine monophosphate levels and heat shock protein-70
expression, and decreases cytochrome P450 activity and
heme oxygenase-1 expression in a variety of tissues, without
conversion to NO, suggesting that it is a signalling molecule
in its own right, such a role remains to be substantiated.
In sum, nitrite appears to represent the most important
storage form of NO, with conversion by nitrite reductases
such as hemoglobin, myoglobin, and XOR resulting in
vasodilatation and cytoprotection. These findings highlight
the importance of the normal physiological actions of nitrite,
but also provide scope for the development of novel
pharmacological and therapeutic uses of nitrite in disease.
CONCLUSION
The endothelium plays a pivotal role in maintaining
cardiovascular homeostasis preventing the initiation and
progress of vascular disease. Endothelium-derived vasodila-
tors including NO, PGI2, and EDHF play a key role in these
processes. Recent reports have further highlighted the
importance of these mediators and mechanisms, which
coordinate their bioactivity to optimize the cytoprotective
effects of the endothelium. This work has also provided
further insight into the gender difference in cardiovascular
disease, with EDHF appearing to play a prominent role in
conferring a cytoprotective phenotype in females. Moreover,
it is becoming clear that eNOS can act in both a pro- and
anti-inflammatory action and therefore is likely to be pivotal
in the initiation and time course of an inflammatory
response, particularly with respect to inflammatory cardio-
vascular disorders. However, it is not solely NOS-derived NO
that mediates many of the beneficial effects of the
endothelium; in recent years, the physiological significance
of nitrite as a store of NO has come to the fore and this
appears to be heightened in pathological episodes associated
with NOS inactivity (e.g., ischemia/hypoxia). Each of these
more recent findings has emphasized new pathways involved
in endothelial biology (Figure 3), and following further
research and understanding of the significance and mechan-
isms of these systems, it is likely that new and improved
treatments for cardiovascular disease will result.
ACKNOWLEDGMENTS
ICV is supported by a British Heart Foundation Project grant, SF by a
Medical Research Council PhD Studentship and AJH by a Wellcome
Trust Senior Research Fellowship.
REFERENCES
1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from
arteries transforms prostaglandin endoperoxides to an unstable
substance that inhibits platelet aggregation. Nature 1976; 263: 663–665.
2. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and
contracting factors. FASEB J 1989; 3: 2007–2018.
3. Ignarro LJ, Buga GM, Wood KS et al. Endothelium-derived relaxing factor
produced and released from artery and vein is nitric oxide. Proc Natl
Acad Sci USA 1987; 84: 9265–9269.
4. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the
biological activity of endothelium-derived relaxing factor. Nature 1987;
327: 524–526.
LPSLPS
XO
TL
R
eNOS
Akt
PO4
Hsp90 CaM L-Arginine
NO
iNOS
CaM
L-Arginine
NO
NF-κB
NO2
–
NO
Relaxation K+
K+
EDHF
[Hyperpolarization]
Na+/K+
ATPase
R
ACh BK
[Ca2+]i
TL
R
KIR
(Hypo)xanthine/NADH
Urate/NAD +
Endothelial
cell
Smooth muscle
cell
Estrogen
Testosterone+
?
?
Figure 3 | Endothelial regulation of vascular smooth muscle tone. Schematic depicting novel mechanisms of endothelial regulation
highlighted in this review, that is, endothelial cell pathways invoked by LPS, nitrite (NO2
), and sex hormones resulting in vasodilatation.
LPS binds to toll-like receptors (TLR) resulting in eNOS activation that consequently stimulates smooth muscle iNOS expression and
function, generating high levels of vasodilator NO. Nitrite is reduced by xanthine oxidase (XO), utilizing either xanthine or nicotinamide
adenine dinucleotide hydreogenase as substrate, to generate NO that results in vasodilatation. Sex hormones interefere with the EDHF
pathway resulting in an upregulation of vasodilatation in females in comparison to males.
848 Kidney International (2006) 70, 840–853
r e v i e w IC Villar et al.: Endothelium-dependent regulation of vascular tone
5. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-
derived hyperpolarizing factor and EDRF from rat blood vessels. Br
J Pharmacol 1988; 95: 1165–1174.
6. Griffith TM. Endothelium-dependent smooth muscle hyperpolarization:
do gap junctions provide a unifying hypothesis? Br J Pharmacol 2004;
141: 881–903.
7. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natriuretic peptide:
more than just a hyperpolarizing factor. Trends Pharmacol Sci 2005; 26:
162–167.
8. Chandrasekharan NV, Dai H, Roos KL et al. COX-3, a cyclooxygenase-1
variant inhibited by acetaminophen and other analgesic/antipyretic
drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;
99: 13926–13931.
9. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular
consequences of COX-2 inhibition: therapeutic challenges and oppor-
tunities. J Clin Invest 2006; 116: 4–15.
10. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system:
understanding the activities of non-steroidal anti-inflammatory drugs.
Nat Rev Drug Discov 2006; 5: 75–86.
11. Moncada SR, Palmer M, Higgs EA. Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–142.
12. Semenza GL. New insights into nNOS regulation of vascular
homeostasis. J Clin Invest 2005; 15: 2976–2978.
13. Hauser B, Radermacher P, Thiemermann C, Matejovic M. Nitric oxide,
bacteria, and host defense in sepsis: who needs what? Shock 2004; 22:
588–590.
14. Edwards G, Dora KA, Gardener MJ et al. K+ is an endothelium-derived
hyperpolarizing factor in rat arteries. Nature 1998; 396: 269–272.
15. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator
of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651–4655.
16. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am
J Cardiol 1995; 75: 3A–10A.
17. Selemidis S, Cocks TM. Endothelium-dependent hyperpolarization as a
remote anti-atherogenic mechanism. Trends Pharmacol Sci 2002; 23:
213–220.
18. Shimokawa H, Yasutake K, Fujii M et al. The importance of the
hyperpolarizing mechanism increases as the vessel size decreases
in endothelium-dependent relaxations in rat mesenteric circulation.
J Cardiovasc Pharmacol 1996; 28: 703–711.
19. Nishikawa Y, Stepp DW, Chilian WM. Nitric oxide exerts feedback
inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am
J Physiol 2000; 279: H459–H465.
20. Bauersachs J, Popp R, Hecker M et al. Nitric oxide attenuates the release
of endothelium-derived hyperpolarizing factor. Circulation 1996; 94:
3341–3347.
21. Wu Y, Huang A, Sun D et al. Gender-specific compensation for the lack
of NO in the mediation of flow-induced arteriolar dilation. Am J Physiol
Heart Circ Physiol 2001; 280: H2456–H2461.
22. Mollace V, Muscoli C, Masini E et al. Modulation of prostaglandin
biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005;
57: 217–252.
23. Deeb RS, Shen H, Gamss C et al. Inducible nitric oxide synthase mediates
prostaglandin H2 synthase nitration and suppresses eicosanoid
production. Am J Pathol 2006; 168: 349–362.
24. Beverelli F, Bea ML, Puybasset L et al. Chronic inhibition of NO synthase
enhances the production of prostacyclin in coronary arteries through
upregulation of the cyclooxygenase type I isoform. Fundam Clin
Pharmacol 1997; 11: 252–259.
25. Doni MG, Whittle BJ, Palmer RM, Moncada S. Actions of nitric oxide on
the release of prostacyclin from bovine endothelial cells in culture. Eur
J Pharmacol 1988; 15: 19–25.
26. Sun D, Huang A, Smith CJ et al. Enhanced release of prostaglandins
contributes to flow-induced arteriolar dilation in eNOS knockout mice.
Circ Res 1999; 85: 288–293.
27. Scotland RS, Chauhan S, Vallance PJ, Ahluwalia A. An endothelium-
derived hyperpolarizing factor-like factor moderates myogenic
constriction of mesenteric resistance arteries in the absence of
endothelial nitric oxide synthase-derived nitric oxide. Hypertension 2001;
38: 833–839.
28. Huang A, Sun D, Smith CJ et al. In eNOS knockout mice skeletal muscle
arteriolar dilation to acetylcholine is mediated by EDHF. Am J Physiol
Heart Circ Physiol 2000; 278: H762–H768.
29. Henrion D, Dechaux E, Dowell FJ et al. Alteration of flow-induced
dilation in mesenteric resistance arteries of L-NAME treated rats and its
partial association with induction of cyclooxygenase-2. Br J Pharmacol
1997; 121: 83–90.
30. Puybasset L, Bea ML, Ghaleh B et al. Coronary and systemic
hemodynamic effects of sustained inhibition of nitric oxide synthesis
in conscious dogs: evidence for cross talk between nitric oxide and
cyclooxygenase in coronary vessels. Circ Res 1996; 79: 343–357.
31. Ahluwalia A. To b’EET or not to b’EET? That is the question! Clin Sci
(London) 2003; 105: 399–401.
32. Bryan Jr RM, You J, Golding EM, Marrelli SP. Endothelium-derived
hyperpolarizing factor: a cousin to nitric oxide and prostacyclin.
Anesthesiology 2005; 102: 1261–1277.
33. Parkington HC, Coleman HA, Tare M. Prostacyclin and endothelium-
dependent hyperpolarization. Pharmacol Res 2004; 49: 509–514.
34. Vanheel B, Van de Voorde J. EDHF and residual NO: different factors.
Cardiovasc Res 2000; 46: 370–375.
35. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 2000; 87: 840–844.
36. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology
to therapy. J Mol Cell Cardiol 1999; 31: 61–74.
37. Huang A, Sun D, Koller A, Kaley G. Gender difference in
flow-induced dilation and regulation of shear stress: role of estrogen
and nitric oxide. Am J Physiol Regul Integr Comp Physiol 1998; 275:
R1571–R1577.
38. Kauser K, Rubanyi GM. Gender difference in bioassayable endothelium-
derived nitric oxide from isolated rat aortae. Am J Physiol Heart Circ
Physiol 1994; 267: H2311–H2317.
39. White RM, Rivera CO, Davison CA. Nitric oxide-dependent and
-independent mechanisms account for gender differences in
vasodilation to acetylcholine. J Pharmacol Exp Ther 2000; 292: 375–380.
40. Perregaux D, Chaudhuri A, Mohanty P et al. Effect of gender differences
and estrogen replacement therapy on vascular reactivity. Metabolism
1999; 48: 227–232.
41. Kawano H, Motoyama T, Kugiyama K et al. Gender difference in
improvement of endothelium-dependent vasodilation after estrogen
supplementation. J Am Coll Cardiol 1997; 30: 914–919.
42. Hisamoto K, Bender JR. Vascular cell signaling by membrane estrogen
receptors. Steroids 2005; 70: 382–387.
43. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular
gender differences. Science 2005; 308: 1583–1587.
44. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and
mortality in the sexes: a 26-year follow-up of the Framingham
population. Am Heart J 1986; 111: 383–390.
45. Triggle CR, Hollenberg M, Anderson TJ et al. The endothelium in health
and disease – a target for therapeutic intervention. J Smooth Muscle Res
2003; 39: 249–267.
46. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of
endothelial dysfunction in children and adults at risk of atherosclerosis.
Lancet 1992; 340: 1111–1115.
47. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible?
J Am Coll Cardiol 1997; 30: 325–333.
48. Scha¨chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary
vasodilator dysfunction on adverse long-term outcome of coronary
heart disease. Circulation 2000; 101: 1899–1906.
49. Hashimoto M, Akishita M, Eto M et al. Modulation of endothelium-
dependent flow-mediated dilatation of the brachial artery by sex and
menstrual cycle. Circulation 1995; 92: 3431–3435.
50. Chan NN, MacAllister RJ, Colhoun HM et al. Changes in
endothelium-dependent vasodilatation and alpha-adrenergic
responses in resistance vessels during the menstrual cycle in healthy
women. J Clin Endocrinol Metab 2001; 86: 2499–2504.
51. Kalantaridou SN, Naka KK, Papanikolaou E et al. Impaired endothelial
function in young women with premature ovarian failure: normalization
with hormone therapy. J Clin Endocrinol Metab 2004; 89: 3907–3913.
52. Pinto S, Virdis A, Ghiadoni L et al. Endogenous estrogen and
acetylcholine-induced vasodilation in normotensive women.
Hypertension 1997; 29: 268–273.
53. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on
endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther
1988; 244: 19–22.
54. Keaney Jr JF, Shwaery GT, Xu A et al. 17 Beta-estradiol preserves
endothelial vasodilator function and limits low-density lipoprotein
oxidation in hypercholesterolemic swine. Circulation 1994; 89:
2251–2259.
55. Reis SE, Gloth ST, Blumenthal RS et al. Ethinyl estradiol acutely
attenuates abnormal coronary vasomotor responses to acetylcholine
in postmenopausal women. Circulation 1994; 89: 52–60.
56. Gilligan DM, Badar DM, Panza JA et al. Acute vascular effects of estrogen
in postmenopausal women. Circulation 1994; 90: 786–791.
Kidney International (2006) 70, 840–853 849
IC Villar et al.: Endothelium-dependent regulation of vascular tone r e v i e w
57. Lieberman EH, Gerhard MD, Uehata A et al. Estrogen improves
endothelium-dependent, flow-mediated vasodilation in
postmenopausal women. Ann Intern Med 1994; 121: 936–941.
58. Gilligan DM, Quyyumi AA, Cannon III RO. Effects of physiological levels
of estrogen on coronary vasomotor function in postmenopausal
women. Circulation 1994; 89: 2545–2551.
59. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A et al. Differential
effects of oral and transdermal estrogen replacement therapy on
endothelial function in postmenopausal women. Circulation 2000; 102:
2687–2693.
60. Wakatsuki A, Ikenoue N, Shinohara K et al. Effect of lower dosage of oral
conjugated equine estrogen on inflammatory markers and endothelial
function in healthy postmenopausal women. Arterioscler Thromb Vasc
Biol 2004; 24: 571–576.
61. Sumino H, Ichikawa S, Ohyama Y et al. Effect of transdermal hormone
replacement therapy on the monocyte chemoattractant protein-1
concentrations and other vascular inflammatory markers and on
endothelial function in postmenopausal women. Am J Cardiol 2005; 96:
148–153.
62. Zegura B, Keber I, Sebestjen M, Borko E. Orally and transdermally
replaced estradiol improves endothelial function equally in middle-aged
women after surgical menopause. Am J Obstet Gynecol 2003; 188:
1291–1296.
63. Taddei S, Virdis A, Ghiadoni L et al. Menopause is associated with
endothelial dysfunction in women. Hypertension 1996; 28: 576–582.
64. Simoncini T, Mannella P, Fornari L et al. Genomic and
non-genomic effects of estrogens on endothelial cells. Steroids 2004;
69: 537–542.
65. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am
J Physiol Regul Integr Comp Physiol 2004; 286: R233–R249.
66. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of
estrogen. FASEB J 1996; 10: 615–624.
67. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-
dependent coronary vasomotor responsiveness in postmenopausal
women with and without estrogen replacement therapy. Am J Cardiol
1994; 73: 951–952.
68. Lopez-Jaramillo P, Diaz LA, Pardo A et al. Estrogen therapy increases
plasma concentrations of nitric oxide metabolites in postmenopausal
women but increases flow-mediated vasodilation only in younger
women. Fertil Steril 2004; 82: 1550–1555.
69. Herrington DM, Espeland MA, Crouse III JR et al. Estrogen replacement
and brachial artery flow-mediated vasodilation in older women.
Arterioscler Thromb Vasc Biol 2001; 21: 1955–1961.
70. Nawate S, Fukao M, Sakuma I et al. Reciprocal changes in
endothelium-derived hyperpolarizing factor and nitric oxide synthase
in the mesenteric artery of adult female rats following ovariectomy.
Br J Pharmacol 2005; 144: 178–189.
71. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart disease in
postmenopausal women. JAMA 1998; 280: 605–613.
72. Writing Group for the Women’s Health Initiative Investigators Risks and
Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women.
Principal results from the women’s health initiative randomized
controlled trial. JAMA 2002; 288: 321–333.
73. Silvestri A, Gambacciani M, Vitale C et al. Different effect of hormone
replacement therapy DHEAS and tibolone on endothelial function in
postmenopausal women with increased cardiovascular risk. Maturitas
2005; 50: 305–311.
74. Cerquetani E, Vitale C, Mercuro G et al. Comparative vascular effects of
hormone replacement therapy and raloxifene in women at increased
cardiovascular risk. Gynecol Endocrinol 2004; 18: 291–298.
75. Koh KK, Jin DK, Yang SH et al. Vascular effects of synthetic or natural
progestagen combined with conjugated equine estrogen in healthy
postmenopausal women. Circulation 2001; 103: 1961–1966.
76. Belchetz PE. Hormone treatment of postmenopausal women. N Engl J
Med 1994; 330: 1062–1071.
77. Grady D, Rubin SM, Petitti DB, Fox CS. Hormone therapy to prevent
disease and prolong life in postmenopausal women. Ann Intern Med
1992; 117: 1016–1037.
78. Miller VM, Vanhoutte PM. Progesterone and modulation of
endothelium-dependent responses in canine coronary arteries. Am
J Physiol 1991; 261: R1022–R1027.
79. Sorensen KE, Dorup I, Hermann AP et al. Combined hormone
replacement therapy does not protect women against the age-related
decline in endothelium-dependent vasomotor function. Circulation
1998; 97: 1234–1238.
80. Kawano H, Motoyama T, Hirai N et al. Effect of medroxyprogesterone
acetate plus estradiol on endothelium-dependent vasodilation in
postmenopausal women. Am J Cardiol 2001; 87: 238–240.
81. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect
of medroxyprogesterone acetate on endothelium-dependent
vasodilation in postmenopausal women receiving estrogen.
Circulation 2001; 104: 1773–1778.
82. English KM, Jones RD, Jones TH et al. Gender differences in the
vasomotor effects of different steroid hormones in rat pulmonary and
coronary arteries. Horm Metab Res 2001; 33: 645–652.
83. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic
vasodilator action of progesterone on primate coronary arteries. J Appl
Physiol 2002; 92: 701–708.
84. Molinari C, Battaglia A, Grossini E et al. The effect of progesterone on
coronary blood flow in anaesthesized pigs. Exp Physiol 2001; 86:
101–108.
85. Chan HY, Yao X, Tsang SY et al. Different role of endothelium/nitric
oxide in 17beta-estradiol- and progesterone-induced relaxation in rat
arteries. Life Sci 2001; 69: 1609–1617.
86. Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al. Metformin
administration improves endothelial function in women with polycystic
ovary syndrome. Eur J Endocrinol 2005; 152: 749–756.
87. Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal
men is reduced by androgen substitution. J Clin Endocrinol Metab 2002;
87: 5030–5037.
88. Jones RD, Pugh PJ, Hall J et al. Altered circulating hormone levels,
endothelial function and vascular reactivity in the testicular feminised
mouse. Eur J Endocrinol 2003; 148: 111–120.
89. Worboys S, Kotsopoulos D, Teede H et al. Evidence that parenteral
testosterone therapy may improve endothelium-dependent and
-independent vasodilation in postmenopausal women already receiving
estrogen. J Clin Endocrinol Metab 2001; 86: 158–161.
90. Malkin CJ, Pugh PJ, West JN et al. Testosterone therapy in men with
moderate severity heart failure: a double-blind randomized placebo
controlled trial. Eur Heart J 2006; 27: 57–64.
91. Lew R, Komesaroff PA, Williams M et al. Endogenous estrogens influence
endothelial function in young men. Circ Res 2003; 93: 1127–1133.
92. Chou TM, Sudhir K, Hutchinson SJ et al. Testosterone induces dilation of
canine coronary conductance and resistance arteries in vivo. Circulation
1996; 94: 2614–2619.
93. Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes
direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther 1996; 277:
34–39.
94. Tep-areenan P, Kendall DA, Randall MD. Mechanisms of vasorelaxation
to 17beta-oestradiol in rat arteries. Eur J Pharmacol 2003; 476: 139–149.
95. Tep-areenan P, Kendall DA, Randall MD. Testosterone-induced vaso-
relaxation in the rat mesenteric arterial bed is mediated predominantly
via potassium channels. Br J Pharmacol 2002; 135: 735–740.
96. Knot HJ, Lounsbury KM, Brayden JE, Nelson MT. Gender differences in
coronary artery diameter reflect changes in both endothelial Ca2+ and
eNOS activity. Am J Physiol Heart Circ Physiol 1999; 276: H961–H969.
97. Wellman GC, Bonev AD, Nelson MT, Brayden JE. Gender differences
in coronary artery diameter involve estrogen, nitric oxide, and
Ca2+-dependent K+ channels. Circ Res 1996; 79: 1024–1030.
98. Squadrito F, Altavilla D, Squadrito G et al. Genistein supplementation
and estrogen replacement therapy improve endothelial dysfunction
induced by ovariectomy in rats. Cardiovasc Res 2000; 45: 454–462.
99. Liu MY, Hattori Y, Fukao M et al. Alterations in EDHF-mediated
hyperpolarization and relaxation in mesenteric arteries of female rats
in long-term deficiency of oestrogen and during oestrus cycle. Br J
Pharmacol 2001; 132: 1035–1046.
100. Chataigneau T, Zerr M, Chataigneau M et al. Chronic treatment with
progesterone but not medroxyprogesterone acetate restores the
endothelial control of vascular tone in the mesenteric artery of
ovariectomized rats. Menopause 2004; 11: 255–263.
101. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric
oxide from aortic rings is greater in female rabbits than in male rabbits:
implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89:
11259–11263.
102. Thompson LP, Pinkas G, Weiner CP. Chronic 17b-estradiol replacement
increases nitric oxide-mediated vasodilation of guinea pig coronary
microcirculation. Circulation 2000; 102: 445–451.
103. Sobey CG, Weiler JM, Boujaoude M, Woodman OL. Effect of short-term
phytoestrogen treatment in male rats on nitric oxide-mediated
responses of carotid and cerebral arteries: comparison with
17beta-estradiol. J Pharmacol Exp Ther 2004; 310: 135–140.
850 Kidney International (2006) 70, 840–853
r e v i e w IC Villar et al.: Endothelium-dependent regulation of vascular tone
104. Scotland RS, Madhani M, Chauhan S et al. Investigation of vascular
responses in endothelial nitric oxide synthase/cyclooxygenase-1
double-knockout mice: key role for endothelium-derived
hyperpolarizing factor in the regulation of blood pressure in vivo.
Circulation 2005; 111: 796–803.
105. Sakuma I, Liu MY, Sato A et al. Endothelium-dependent
hyperpolarization and relaxation in mesenteric arteries of middle-aged
rats: influence of oestrogen. Br J Pharmacol 2002; 135: 48–54.
106. Bolego C, Cignarella A, Ruzza R et al. Differential effects of low- and
high-dose estrogen treatments on vascular responses in female rats. Life
Sci 1997; 60: 2291–2302.
107. Andersen HL, Weis JU, Fjalland B, Korsgaard N. Effect of acute and
long-term treatment with 17-beta-estradiol on the vasomotor responses
in the rat aorta. Br J Pharmacol 1999; 126: 159–168.
108. Gonzales RJ, Walker BR, Kanagy NL. 17beta-estradiol increases nitric
oxide-dependent dilation in rat pulmonary arteries and thoracic aorta.
Am J Physiol 2001; 280: L555–L564.
109. Sanchez A, Gomez MJ, Dorantes AL et al. The effect of ovariectomy on
depressed contractions to phenylephrine and KCl and increased
relaxation to acetylcholine in isolated aortic rings of female compared to
male rabbits. Br J Pharmacol 1996; 118: 2017–2022.
110. Barber DA, Miller VM. Gender differences in endothelium-dependent
relaxations do not involve NO in porcine coronary arteries. Am J Physiol
Heart Circ Physiol 1997; 273: H2325–H2332.
111. Huang A, Sun D, Carroll MA et al. EDHF mediates flow-induced dilation
in skeletal muscle arterioles of female eNOS–KO mice. Am J Physiol Heart
Circ Physiol 2001; 280: H2462–H2469.
112. Forte P, Kneale BJ, Milne E et al. Evidence for a difference in nitric oxide
biosynthesis between healthy women and men. Hypertension 1998; 32:
730–734.
113. Sudhir K, Jennings GL, Funder JW, Komesaroff PA. Estrogen enhances
basal nitric oxide release in the forearm vasculature in perimenopausal
women. Hypertension 1996; 28: 330–334.
114. Rosselli M, Imthurn B, Keller PJ et al. Circulating nitric oxide (nitrite/
nitrate) levels in postmenopausal women substituted with 17b-estradiol
and norethisterone acetate. Hypertension 1995; 25: 848–853.
115. Yang S, Bae L, Zhang L. Estrogen increases eNOS and NOx release in
human coronary artery endothelium. J Cardiovasc Pharmacol 2000; 36:
242–247.
116. Thompson J, Khalil RA. Gender differences in the regulation of vascular
tone. Clin Exp Pharmacol Physiol 2003; 30: 1–15.
117. Haynes MP, Russell KS, Bender JR. Molecular mechanisms of estrogen
actions on the vasculature. J Nucl Cardiol 2000; 7: 500–508.
118. Hernandez I, Delgado JL, Diaz J et al. 17b-Estradiol prevents oxidative
stress and decreases blood pressure in ovariectomized rats. Am J Physiol
Regul Integr Comp Physiol 2000; 279: R1599–R1605.
119. Gragasin FS, Xu Y, Arenas IA et al. Estrogen reduces angiotensin
II-induced nitric oxide synthase and NAD(P)H oxidase expression
in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 38–44.
120. Wagner AH, Schroeter MR, Hecker M. 17b-Estradiol inhibition of NADPH
oxidase expression in human endothelial cells. FASEB J 2001; 15:
2121–2130.
121. Barbacanne MA, Rami J, Michel JB et al. Estradiol increases rat aorta
endothelium-derived relaxing factor (EDRF) activity without changes in
endothelial NO synthase gene expression: possible role of decreased
endothelium-derived superoxide anion production. Cardiovasc Res 1999;
41: 672–681.
122. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer
surfaces of isolated endometrial cells. Nature 1977; 265: 69–72.
123. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen
receptor in cultured endothelial cells. A potential mechanism for steroid
hormone regulation of endothelial function. Circulation 1996; 94:
727–733.
124. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS et al. Estrogen acutely
stimulates nitric oxide synthase activity in fetal pulmonary artery
endothelium. Am J Physiol 1997; 273: L119–L126.
125. Caulin-Glaser T, Watson CA, Bender JR. 17b-Estradiol regulation of
human endothelial cell basal nitric oxide release, independent of
cytosolic Ca2+ mobilization. Circ Res 1997; 81: 885–892.
126. Chen Z, Yuhanna IS, Galcheva-Gargova Z et al. Estrogen receptor a
mediates the nongenomic activation of endothelial nitric oxide synthase
by estrogen. J Clin Invest 1999; 103: 401–406.
127. Russell KS, Haynes MP, Sinha D et al. Human vascular endothelial
cells contain membrane binding sites for estradiol, which mediate
rapid intracellular signaling. Proc Natl Acad Sci USA 2000; 97:
5930–5935.
128. Cirino G, Fiorucci S, Sessa WC. Endothelial nitric oxide synthase: the
Cinderella of inflammation? Trends Pharmacol Sci 2003; 24: 91–95.
129. Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-
derived nitric oxide production by the protein kinase Akt. Nature 1999;
399: 597–601.
130. Woodman OL, Missen MA, Boujaoude M. Daidzein and 17[beta]-
estradiol enhance nitric oxide synthase activity associated with an
increase in calmodulin and a decrease in caveolin-1. J Cardiovasc
Pharmacol 2004; 44: 155–163.
131. Turi A, Kiss AL, Mullnar N. Estrogen downregulates the number of
caveolae and the level of caveolin in uterine smooth muscle. Cell Biol Int
2001; 25: 785–794.
132. Xu HL, Galea E, Santizo RA et al. The key role of caveolin-1 in estrogen-
mediated regulation of endothelial nitric oxide synthase function in
cerebral arterioles in vivo. J Cereb Blood Flow Metab 2001; 21: 907–913.
133. Jayachandran M, Hayashi T, Sumi D et al. Temporal effects of 17beta-
estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial
cells. Am J Physiol Heart Circ Physiol 2001; 281: H1327–H1333.
134. Hisamoto K, Ohmichi M, Kurachi H et al. Estrogen induces the Akt-
dependent activation of endothelial nitric-oxide synthase in vascular
endothelial cells. J Biol Chem 2001; 276: 3459–3467.
135. Cox MW, Fu W, Chai H et al. Effects of progesterone and estrogen on
endothelial dysfunction in porcine coronary arteries. J Surg Res 2005;
124: 104–111.
136. Honda H, Unemoto T, Kogo H. Different mechanisms for testosterone-
induced relaxation of aorta between normotensive and spontaneously
hypertensive rats. Hypertension 1999; 34: 1232–1236.
137. Yue P, Chatterjee K, Beale C et al. Testosterone relaxes rabbit coronary
arteries and aorta. Circulation 1995; 91: 1154–1160.
138. Geary GG, Krause DN, Duckles SP. Estrogen reduces mouse
cerebral artery tone through endothelial NOS- and cyclooxygenase-
dependent mechanisms. Am J Physiol Heart Circ Physiol 2000; 279:
H511–H519.
139. Ospina JA, Krause DN, Duckles SP. 17b-Estradiol increases rat
cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1
and prostacyclin synthase. Stroke 2002; 33: 600–605.
140. O’Sullivan MG, Goodrich JA, Adams MR. Increased prostacyclin synthesis
by atherosclerotic arteries from estrogen-treated monkeys. Life Sci 2001;
69: 395–401.
141. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates
cyclooxygenase-1 gene expression in ovine fetal pulmonary artery
endothelium. J Clin Invest 1998; 102: 176–183.
142. Rupnow HL, Phernetton TM, Modrick ML et al. Endothelial vasodilator
production by uterine and systemic arteries. VIII. Estrogen and
progesterone effects on cPLA2, COX-1, and PGIS protein expression. Biol
Reprod 2002; 66: 468–474.
143. Davidge ST, Zhang Y. Estrogen replacement suppresses a prostaglandin
H synthase-dependent vasoconstrictor in rat mesenteric arteries. Circ
Res 1998; 83: 388–395.
144. Armstrong SJ, Zhang Y, Stewart KG, Davidge ST. Estrogen replacement
reduces PGHS-2-dependent vasoconstriction in the aged rat. Am J
Physiol Heart Circ Physiol 2002; 283: H893–H898.
145. Woodman OL, Boujaoude M. Chronic treatment of male rats with
daidzein and 17[beta]-oestradiol induces the contribution of EDHF
to endothelium-dependent relaxation. Br J Pharmacol 2004; 141:
322–328.
146. Jiang C, Sarrel PM, Lindsay DC et al. Endothelium-independent
relaxation of rabbit coronary artery by 17b-estradiol in vitro. Br J
Pharmacol 1991; 104: 1033–1037.
147. Huang A, Sun D, Wu Z et al. Estrogen elicits cytochrome P450-mediated
flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt
phosphorylation in genomic regulation. Circ Res 2004; 94: 245–252.
148. Li X, Geary G, Gonzales RJ et al. Effect of estrogen on cerebrovascular
prostaglandins is amplified in mice with dysfunctional NOS. Am J Physiol
Heart Circ Physiol 2004; 287: H588–H594.
149. Case J, Davison CA. Estrogen alters relative contributions of nitric oxide
and cyclooxygenase products to endothelium-dependent vasodilation.
J Pharmacol Exp Ther 1999; 291: 524–530.
150. Selles J, Polini N, Alvarez C, Massheimer V. Nongenomic action of
progesterone in rat aorta: role of nitric oxide and prostaglandins. Cell
Signal 2002; 14: 431–436.
151. Hermenegildo C, Oviedo PJ, Garcia-Martinez MC et al. Progestogens
stimulate prostacyclin production by human endothelial cells. Hum
Reprod 2005; 20: 1554–1561.
152. Mikkola T, Viinikka L, Ylikorkala O. Administration of transdermal
estrogen without progestin increases the capacity of plasma and serum
Kidney International (2006) 70, 840–853 851
IC Villar et al.: Endothelium-dependent regulation of vascular tone r e v i e w
to stimulate prostacyclin production in human vascular endothelial cells.
Fertil Steril 2000; 73: 72–74.
153. Nakao J, Chang WC, Murota SI, Orimo H. Testosterone inhibits
prostacyclin production in rat aortic smooth muscle cells in culture.
Atherosclerosis 1981; 39: 203–209.
154. Wakasugi M, Noguchi T, Kazama YI et al. The effects of sex hormones on
the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins
1989; 37: 401–410.
155. Chataigneau T, Schini-Kerth VB. Vascular effects of ovariectomy and
chronic oestrogen treatment in rats: controversy or experimental
protocol diversity? Br J Pharmacol 2005; 144: 161–163.
156. Corriu C, Feletou M, Edwards G et al. Differential effects of prostacyclin
and iloprost in the isolated carotid artery of the guinea-pig. Eur J
Pharmacol 2001; 426: 89–94.
157. Cohen RA, Plane F, Najibi S et al. Nitric oxide is the mediator of both
endothelium-dependent relaxation and hyperpolarization of the rabbit
carotid artery. Proc Natl Acad Sci USA 1997; 94: 4193–4198.
158. Pak KJ, Geary GG, Duckles SP, Krause DN. Male–female differences in the
relative contribution of endothelial vasodilators released by rat tail
artery. Life Sci 2002; 71: 1633–1642.
159. McCulloch AI, Randall MD. Sex differences in the relative contributions
of nitric oxide and EDHF to agonist-stimulated endothelium-dependent
relaxations in the rat isolated mesenteric arterial bed. Br J Pharmacol
1998; 123: 1700–1706.
160. Gerber RT, Anwar MA, Poston L. Enhanced acetylcholine induced
relaxation in small mesenteric arteries from pregnant rats: an important
role for endothelium-derived hyperpolarizing factor (EDHF). Br J
Pharmacol 1998; 125: 455–460.
161. Huang A, Wu Y, Sun D et al. Effect of estrogen on flow-induced dilation
in NO deficiency: role of prostaglandins and EDHF. J Appl Physiol 2001;
91: 2561–2566.
162. Xu HL, Ye S, Baughman VL et al. The role of the glia limitans in
ADP-induced pial arteriolar relaxation in intact and ovariectomized
female rats. Am J Physiol Heart Circ Physiol 2005; 288: H382–H388.
163. Liu MY, Hattori Y, Sato A et al. Ovariectomy attenuates hyperpolarization
and relaxation mediated by endothelium-derived hyperpolarizing factor
in female rat mesenteric artery: a concomitant decrease in connexin-43
expression. J Cardiovasc Pharmacol 2002; 40: 938–948.
164. Golding EM, Kepler TE. Role of estrogen in modulating EDHF-mediated
dilations in the female rat middle cerebral artery. Am J Physiol Heart Circ
Physiol 2001; 280: H2417–H2423.
165. Xu HL, Santizo RA, Koenig HM, Pelligrino DA. Chronic estrogen
depletion alters adenosine diphosphate-induced pial arteriolar
dilation in female rats. Am J Physiol Heart Circ Physiol 2001; 282:
H2105–H2112.
166. Sandow SL, Hill CE. Incidence of myoendothelial gap junctions in the
proximal and distal mesenteric arteries of the rat is suggestive of a role
in endothelium-derived hyperpolarizing factor-mediated responses. Circ
Res 2000; 86: 341–346.
167. Acuff CG, Huang H, Steinhelper ME. Estradiol induces C-type natriuretic
peptide gene expression in mouse uterus. Am J Physiol Heart Circ Physiol
1997; 273: H2672–H2677.
168. Barber DA, Burnett Jr JC, Fitzpatrick LA et al. Gender and relaxation to
C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc
Pharmacol 1998; 32: 5–11.
169. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type
natriuretic peptide accounts for the biological activity of endothelium-
derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003; 100:
1426–1431.
170. Hobbs A, Foster P, Prescott C et al. Natriuretic peptide receptor-C
regulates coronary blood flow and prevents myocardial ischemia/
reperfusion injury: novel cardioprotective role for endothelium-derived
C-type natriuretic peptide. Circulation 2004; 110: 1231–1235.
171. Node K, Kitakaze M, Kosaka H et al. Roles of NO and Ca2+-activated K+
channels in coronary vasodilation induced by 17b-estradiol in ischemic
heart failure. FASEB J 1997l; 11: 793–799.
172. Nathan CF, Hibbs Jr JB. Role of nitric oxide synthesis in macrophage
antimicrobial activity. Curr Opin Immunol 1991; 3: 65–70.
173. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function.
Annu Rev Immunol 1997; 15: 323–350.
174. Xie Q, Nathan C. The high-output nitric oxide pathway: role and
regulation. J Leukocyte Biol 1994; 56: 576–582.
175. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of
inducible nitric oxide synthase. Biol Chem 2003; 384: 1343–1364.
176. Bush PA, Gonzalez NE, Griscavage JM, Ignarro LJ. Nitric oxide synthase
from cerebellum catalyzes the formation of equimolar quantities of
nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun
1992; 185: 960–966.
177. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ. Negative feedback
regulation of endothelial cell function by nitric oxide. Circ Res 1993; 73:
808–812.
178. Parker JL, Adams HR. Selective inhibition of endothelium-dependent
vasodilator capacity by Escherichia coli endotoxemia. Circ Res 1993; 72:
539–551.
179. Umans JG, Wylam ME, Samsel RW et al. Effects of endotoxin in vivo on
endothelial and smooth-muscle function in rabbit and rat aorta. Am Rev
Respir Dis 1993; 148: 1638–1645.
180. Stoclet JC, Muller B, Gyorgy K et al. The inducible nitric oxide synthase
in vascular and cardiac tissue. Eur J Pharmacol 1999; 375:
139–155.
181. Rees DD, Monkhouse JE, Cambridge D, Moncada S. Nitric oxide and the
haemodynamic profile of endotoxin shock in the conscious mouse. Br J
Pharmacol 1998; 124: 540–546.
182. Chauhan SD, Seggara G, Vo PA et al. Protection against lipopolysac-
charide-induced endothelial dysfunction in resistance and conduit
vasculature of iNOS knockout mice. FASEB J 2003; 17: 773–775.
183. Mathewson AM, Wadsworth RM. Induction of iNOS restricts functional
activity of both eNOS and nNOS in pig cerebral artery. Nitric Oxide 2004;
11: 331–339.
184. Schwartz D, Mendonca M, Schwartz I et al. Inhibition of constitutive
nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS
after lipopolysaccharide administration provokes renal dysfunction in
rats. J Clin Invest 1997; 100: 439–448.
185. Piepot HA, Boer C, Groeneveld AB et al. Lipopolysaccharide impairs
endothelial nitric oxide synthesis in rat renal arteries. Kidney Int 2000; 57:
2502–2510.
186. Connelly L, Palacios-Callender M, Ameixa C et al. Biphasic regulation of
NF-kappa B activity underlies the pro- and anti-inflammatory actions of
nitric oxide. J Immunol 2001; 166: 3873–3881.
187. Sherman MP, Aeberhard EE, Wong VZ et al. J pyrrolidine
dithiocarbamate inhibits induction of nitric oxide synthase activity
in rat alveolar macrophages. Biochem Biophys Res Commun 1993;
191: 1301–1308.
188. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding
calcium-independent nitric oxide synthase confers inducibility by
interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993;
177: 1779–1784.
189. Umansky V, Hehner SP, Dumont A et al. Co-stimulatory effect of nitric
oxide on endothelial NF-kappaB implies a physiological self-amplifying
mechanism. Eur J Immunol 1998; 28: 2276–2282.
190. Connelly L, Jacobs AT, Palacios-Callender M et al. Macrophage
endothelial nitric-oxide synthase autoregulates cellular activation and
pro-inflammatory protein expression. J Biol Chem 2003; 278:
26480–26487.
191. Francis SA, Vo PA, Ahluwalia A. Regulatory role of eNOS on vascular
iNOS expression and function in endotoxaemia. Proc Br Pharmacol Soc
2004; 2(4): abst128P.
192. Connelly L, Madhani M, Hobbs AJ. Resistance to endotoxic shock in
endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-
inflammatory role for eNOS-derived no in vivo. J Biol Chem 2005; 280:
10040–10046.
193. Vo PA, Lad B, Tomlinson JA et al. Autoregulatory role of endothelium-
derived nitric oxide (NO) on lipopolysaccharide-induced vascular
inducible NO synthase expression and function. J Biol Chem 2005; 280:
7236–7243.
194. Stamler JS, Jaraki O, Osborne J et al. Nitric oxide circulates in mammalian
plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl
Acad Sci USA 1992; 89: 7674–7677.
195. Rassaf T, Kleinbongard P, Preik M et al. Plasma nitrosothiols contribute
to the systemic vasodilator effects of intravenously applied NO:
experimental and clinical study on the fate of NO in human blood. Circ
Res 2002; 91: 470–477.
196. McMahon TJ, Moon RE, Luschinger BP et al. Nitric oxide in the human
respiratory cycle. Nat Med 2002; 8: 711–717.
197. Stamler JS, Jia L, Eu JP et al. Blood flow regulation by
S-nitrosohemoglobin in the physiological oxygen gradient. Science
1997; 276: 2034–2037.
198. Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide
bioactivity. Nature 2001; 409: 622–626.
199. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a
dynamic activity of blood involved in vascular control. Nature 1996; 380:
221–226.
852 Kidney International (2006) 70, 840–853
r e v i e w IC Villar et al.: Endothelium-dependent regulation of vascular tone
200. Luchsinger BP, Rich EN, Gow AJ et al. Routes to S-nitroso-hemoglobin
formation with heme redox and preferential reactivity in the beta
subunits. Proc Natl Acad Sci USA 2003; 100: 461–466.
201. Hilliquin P, Borderie D, Hernvann A et al. Nitric oxide as S-nitrosoproteins
in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1512–1517.
202. Rocks SA, Davies CA, Hicks SL et al. Measurement of S-nitrosothiols in
extracellular fluids from healthy human volunteers and rheumatoid
arthritis patients, using electron paramagnetic resonance spectrometry.
Free Radic Biol Med 2005; 39: 937–948.
203. Bryan NS, Rassaf T, Rodriguez J, Feelisch M. Bound NO in human red
blood cells: fact or artifact? Nitric Oxide 2004; 10: 221–228.
204. Gladwin MT, Shelhamer JH, Schechter AN et al. III: Role of circulating
nitrite and S-nitrosohemoglobin in the regulation of regional blood flow
in humans. Proc Natl Acad Sci USA 2000; 97: 11482–11487.
205. Gladwin MT, Ognibene FP, Pannell LK et al. Relative role of heme
nitrosylation and beta-cysteine 93 nitrosation in the transport and
metabolism of nitric oxide by hemoglobin in the human circulation.
Proc Natl Acad Sci USA 2000; 97: 9943–9948.
206. Joshi MS, Ferguson Jr TB, Han TH et al. Nitric oxide is consumed, rather
than conserved, by reaction with oxyhemoglobin under physiological
conditions. Proc Natl Acad Sci USA 2002; 99: 10341–10346.
207. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for
systemic generation of nitric oxide. Free Radical Biol Med 2004; 37:
395–400.
208. Pannala AS, Mani AR, Spencer JP et al. The effect of dietary nitrate on
salivary, plasma, and urinary nitrate metabolism in humans. Free Radical
Biol Med 2003; 34: 576–584.
209. Giustarini D, Dalle-Donne I, Colombo R et al. Adaptation of the Griess
reaction for detection of nitrite in human plasma. Free Radical Res 2004;
38: 1235–1240.
210. Kleinbongard P, Dejam A, Lauer T et al. Plasma nitrite reflects
constitutive nitric oxide synthase activity in mammals. Free Radical Biol
Med 2003; 35: 790–796.
211. Lauer T, Preik M, Rassaf T et al. Plasma nitrite rather than nitrate reflects
regional endothelial nitric oxide synthase activity but lacks intrinsic
vasodilator action. Proc Natl Acad Sci USA 2001; 98: 12814–12819.
212. Dejam A, Hunter CJ, Pelletier MM et al. Erythrocytes are the major
intravascular storage sites of nitrite in human blood. Blood 2005; 106:
734–739.
213. Bryan NS, Fernandez BO, Bauer SM et al. Nitrite is a signaling molecule
and regulator of gene expression in mammalian tissues. Nat Chem Biol
2005; 1: 290–297.
214. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent
formation of nitric oxide in biological tissues. Nat Med 1995; 1:
804–809.
215. Benjamin N, O’Driscoll F, Dougall H et al. Stomach NO synthesis. Nature
1994; 368: 502.
216. Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and
human health. Nat Rev Microbiol 2004; 2: 593–602.
217. Spiegelhalder B, Eisenbrand G, Preussmann R. Influence of dietary
nitrate on nitrite content of human saliva: possible relevance to in vivo
formation of N-nitroso compounds. Food Cosmet Toxicol 1976; 14:
545–548.
218. Furchgott RF, Bhadrakom S. Reactions of strips of rabbit aorta to
epinephrine, isopropylarterenol, sodium nitrite and other drugs.
J Pharmacol Exp Ther 1953; 108: 129–143.
219. Modin A, Bjorne H, Herulf M et al. Nitrite-derived nitric oxide: a possible
mediator of ‘acidic-metabolic’ vasodilation. Acta Physiol Scand 2001;
171: 9–16.
220. Beier S, Classen HG, Loeffler K et al. Antihypertensive effect of oral nitrite
uptake in the spontaneously hypertensive rat. Arzneimittelforschung
1995; 45: 258–261.
221. Haas M, Classen HG, Thoni H et al. Persistent antihypertensive effect of
oral nitrite supplied up to one year via the drinking water in
spontaneously hypertensive rats. Arzneimittelforschung 1999; 49:
318–323.
222. Classen HG, Stein-Hammer C, Thoni H. Hypothesis: the effect of oral
nitrite on blood pressure in the spontaneously hypertensive rat. Does
dietary nitrate mitigate hypertension after conversion to nitrite? J Am
Coll Nutr 1990; 9: 500–502.
223. Doyle MP, Pickering RA et al. Kinetics and mechanism of the oxidation of
human deoxyhemoglobin by nitrites. J Biol Chem 1981; 256:
12393–12398.
224. Cosby K, Partovi KS, Crawford JH et al. Nitrite reduction to nitric oxide by
deoxyhemoglobin vasodilates the human circulation. Nat Med 2003; 9:
1498–1505.
225. Tsuchiya K, Kanematsu Y, Yoshizumi M et al. Nitrite is an alternative
source of NO in vivo. Am J Physiol Heart Circ Physiol 2005; 288:
H2163–H2170.
226. Tsuchiya K, Takiguchi Y, Okamoto M et al. Malfunction of vascular
control in lifestyle-related diseases: formation of systemic hemoglobin-
nitric oxide complex (HbNO) from dietary nitrite. J Pharmacol Sci 2004;
96: 395–400.
227. Webb A, Bond R, McLean P et al. Reduction of nitrite to nitric oxide
during ischemia protects against myocardial ischemia–reperfusion
damage. Proc Natl Acad Sci USA 2004; 101: 13683–13688.
228. Zhang Z, Naughton D, Winyard PG et al. Generation of nitric oxide by a
nitrite reductase activity of xanthine oxidase: a potential pathway for
nitric oxide formation in the absence of nitric oxide synthase activity.
Biochem Biophys Res Commun 1998; 249: 767–772.
229. Godber BL, Doel JJ, Sapkota GP et al. Reduction of nitrite to nitric oxide
catalyzed by xanthine oxidoreductase. J Biol Chem 2000; 275:
7757–7763.
230. Spiekermann S, Landmesser U, Dikalov S et al. Electron spin
resonance characterization of vascular xanthine and NAD(P)H
oxidase activity in patients with coronary artery disease: relation to
endothelium-dependent vasodilation. Circulation 2003; 107:
1383–1389.
231. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease:
molecular mechanisms and pathophysiological implications. J Physiol
2004; 555: 589–606.
232. Duranski MR, Greer JJ, Dejam A et al. Cytoprotective effects of nitrite
during in vivo ischemia–reperfusion of the heart and liver. J Clin Invest
2005; 115: 1232–1240.
233. Hunter CJ, Dejam A, Blood AB et al. Inhaled nebulized nitrite is a
hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat
Med 2004; 10: 1122–1127.
234. Pluta RM, Dejam A, Grimes G et al. Nitrite infusions to prevent delayed
cerebral vasospasm in a primate model of subarachnoid hemorrhage.
JAMA 2005; 293: 1477–1484.
235. Reutov VP, Sorokina EG. NO-synthase and nitrite-reductase components
of nitric oxide cycle. Biochemistry (Moscow) 1998; 63: 874–884.
236. Kozlov AV, Staniek K, Nohl H. Nitrite reductase activity is a novel
function of mammalian mitochondria. FEBS Lett 1999; 454:
127–130.
237. Reutov VP. Biochemical predetermination of the NO synthase and nitrite
reductase components of the nitric oxide cycle. Biochemistry (Moscow)
1999; 64: 528–542.
Kidney International (2006) 70, 840–853 853
IC Villar et al.: Endothelium-dependent regulation of vascular tone r e v i e w
